QPT — Quest PharmaTech Income Statement
0.000.00%
- CA$8.46m
- CA$9.27m
- 72
- 94
- 72
- 94
Annual income statement for Quest PharmaTech, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS/A | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 13.6 | -127 | 0.521 | 0.384 | 1.16 |
Operating Profit | -13.6 | 127 | -0.521 | -0.384 | -1.16 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.3 | 190 | -85 | -64.9 | -3.02 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.3 | 190 | -85 | -64.9 | -3.02 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.18 | 190 | -85 | -64.9 | -3.02 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.18 | 190 | -85 | -64.9 | -3.02 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.037 | 0.367 | -0.507 | -0.388 | -0.019 |